Quarterly Result14 May 2026, 04:41 pm
Akums FY26: Revenue ₹4,359 Cr, PAT ₹276 Cr; Dividend Announced
AI Summary
Akums Drugs & Pharmaceuticals Ltd. reported its Q4 and full-year FY26 results, showcasing healthy revenue and strong EBITDA growth. Q4 FY26 operating revenue reached ₹1,158 crore, a 9.7% YoY increase. Adj EBITDA stood at ₹152 crore, up 61.6% YoY, with margins improving to 13.1%. Adj PAT grew by 135% YoY to ₹83 crore. For the full year FY26, operating revenue was ₹4,359 crore, up 5.9% YoY, with Adj EBITDA increasing by 13.3% to ₹522 crore and Adj PAT growing by 27.3% to ₹276 crore. The board recommended a final dividend of ₹1 per equity share and a special dividend of ₹2 per equity share.
Key Highlights
- Q4 FY26 revenue grew 9.7% YoY to ₹1,158 crore; Adj EBITDA up 61.6% to ₹152 crore.
- FY26 revenue increased 5.9% YoY to ₹4,359 crore; Adj EBITDA rose 13.3% to ₹522 crore.
- CDMO segment was a key growth driver, with Q4 revenue at ₹952 crore and EBITDA up 54.9%.
- Board recommends a final dividend of ₹1 per share and a special dividend of ₹2 per share.
- Akums made its first commercial supply of formulations to Europe in FY26.